Update on prostate cancer screening.

M. Lazzaro, M. Thompson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Prostate cancer is the second most common cause of death in men; it is diagnosed in about 1 in 10 men. Significant risk factors include, but are not limited to, race and age; the peak age at diagnosis is the seventh decade. A through screening program, sensitive to the risk factors and targeted to patients with curable prostate cancer, can decrease the rates of mortality and morbidity associated with this disease, without overtreating patients who have latent cancer. Screening methods include annual digital rectal examinations and prostate-specific antigen tests. Staging is important when treatment options are considered and treatment morbidity rate is weighed against disease mortality rate. Research concerning genetics changes and chemoprevention trials of vitamins and hormonal agents are targeted toward primary prevention. Implications for practice should include primary prevention, screening and detection, public education, and monitoring of the disease.

Original languageEnglish (US)
JournalLippincott's primary care practice
Volume1
Issue number4
StatePublished - 1997
Externally publishedYes

Fingerprint

Early Detection of Cancer
Prostatic Neoplasms
Primary Prevention
Morbidity
Digital Rectal Examination
Genetic Research
Mortality
Chemoprevention
Prostate-Specific Antigen
Vitamins
Cause of Death
Education
Therapeutics
Neoplasms

Cite this

Update on prostate cancer screening. / Lazzaro, M.; Thompson, M.

In: Lippincott's primary care practice, Vol. 1, No. 4, 1997.

Research output: Contribution to journalArticle

Lazzaro, M & Thompson, M 1997, 'Update on prostate cancer screening.', Lippincott's primary care practice, vol. 1, no. 4.
Lazzaro, M. ; Thompson, M. / Update on prostate cancer screening. In: Lippincott's primary care practice. 1997 ; Vol. 1, No. 4.
@article{1146f2b936d3460f9ea3d0eef89b3c57,
title = "Update on prostate cancer screening.",
abstract = "Prostate cancer is the second most common cause of death in men; it is diagnosed in about 1 in 10 men. Significant risk factors include, but are not limited to, race and age; the peak age at diagnosis is the seventh decade. A through screening program, sensitive to the risk factors and targeted to patients with curable prostate cancer, can decrease the rates of mortality and morbidity associated with this disease, without overtreating patients who have latent cancer. Screening methods include annual digital rectal examinations and prostate-specific antigen tests. Staging is important when treatment options are considered and treatment morbidity rate is weighed against disease mortality rate. Research concerning genetics changes and chemoprevention trials of vitamins and hormonal agents are targeted toward primary prevention. Implications for practice should include primary prevention, screening and detection, public education, and monitoring of the disease.",
author = "M. Lazzaro and M. Thompson",
year = "1997",
language = "English (US)",
volume = "1",
journal = "Lippincott's primary care practice",
issn = "1088-5471",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Update on prostate cancer screening.

AU - Lazzaro, M.

AU - Thompson, M.

PY - 1997

Y1 - 1997

N2 - Prostate cancer is the second most common cause of death in men; it is diagnosed in about 1 in 10 men. Significant risk factors include, but are not limited to, race and age; the peak age at diagnosis is the seventh decade. A through screening program, sensitive to the risk factors and targeted to patients with curable prostate cancer, can decrease the rates of mortality and morbidity associated with this disease, without overtreating patients who have latent cancer. Screening methods include annual digital rectal examinations and prostate-specific antigen tests. Staging is important when treatment options are considered and treatment morbidity rate is weighed against disease mortality rate. Research concerning genetics changes and chemoprevention trials of vitamins and hormonal agents are targeted toward primary prevention. Implications for practice should include primary prevention, screening and detection, public education, and monitoring of the disease.

AB - Prostate cancer is the second most common cause of death in men; it is diagnosed in about 1 in 10 men. Significant risk factors include, but are not limited to, race and age; the peak age at diagnosis is the seventh decade. A through screening program, sensitive to the risk factors and targeted to patients with curable prostate cancer, can decrease the rates of mortality and morbidity associated with this disease, without overtreating patients who have latent cancer. Screening methods include annual digital rectal examinations and prostate-specific antigen tests. Staging is important when treatment options are considered and treatment morbidity rate is weighed against disease mortality rate. Research concerning genetics changes and chemoprevention trials of vitamins and hormonal agents are targeted toward primary prevention. Implications for practice should include primary prevention, screening and detection, public education, and monitoring of the disease.

UR - http://www.scopus.com/inward/record.url?scp=0031229740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031229740&partnerID=8YFLogxK

M3 - Article

C2 - 9313534

AN - SCOPUS:0031229740

VL - 1

JO - Lippincott's primary care practice

JF - Lippincott's primary care practice

SN - 1088-5471

IS - 4

ER -